Cipla vs Sbilife Q1 FY24

Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY). EBITDA margin expanded to 23.6%, aided by favorable mix and operational efficiencies. PAT stood at INR 996 crore (15.7% of sales). The US complex portfolio, including Lanreotide (18% market share) and stabilized Albuterol, powered growth, while India's chronic share rose to 60%. Management raised full-year EBITDA margin guidance to ~23% (from 22% earlier). Key pipeline catalysts include Symbicort filing by year-end, 4-5 peptide launches over two years, and de-risking of Advair and Abraxane. Risks include US FDA classification for Indore facility and potential pricing pressure in the US generics market.

Guidance read

Full-year EBITDA margin target of ~23%: Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets. Symbicort filing by end of FY24: Cipla expects to file generic Symbicort (respiratory product) by the end of calendar year 2023. 4-5 peptide launches in next two years: Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period. Advair launch within 12 months via de-risking: Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.

Risk read

Key risks include US FDA classification for Indore facility pending — Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.; Albuterol recall and market share loss — Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.; Potential pricing pressure in US generics — While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.; Goa facility re-inspection uncertainty — Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products..

Promise ledger

Scorecard data is being built as historical quarters are processed.

SBI Life reported a decent Q1 FY24 on a high base, with individual new business premium growing 18% YoY to INR 40.6 billion and PAT up 45% YoY to INR 3.8 billion. Growth was driven by strong annuity (individual annuity up 129%) and ULIP traction, while non-par savings saw a temporary dip due to last year's pent-up demand. VNB margin came in at 28.8%, down from 30.2% in Q1 FY23, primarily due to product mix shift. Management reiterated a 20-25% growth aspiration for FY24 and expects margins to remain range-bound around 28-30%. Key risks include potential upward pressure on distributor commissions following regulatory changes (EOM guidelines) and a slight dip in 13-month persistency to 85.1%.

Guidance read

FY24 growth aspiration of 20-25%: Management expects to deliver better than industry growth, targeting 20-25% growth in individual rated premium for FY24. VNB margin to remain range-bound around 28-30%: Management expects VNB margins to stay in the 28-30% range, with no significant expansion or compression expected. Non-par share expected at 24-25% of business: CFO indicated non-par share should normalize to around 24-25% of business for the full year, similar to FY23.

Risk read

Key risks include Potential margin pressure from increased distributor commissions — Regulatory changes (EOM guidelines) may lead to higher commission payouts, especially to SBI, potentially compressing VNB margins.; Persistency decline in near-term cohorts — 13-month and 25-month persistency dipped slightly, which could impact future renewal premiums and embedded value if not reversed.; High base effect may constrain growth in coming quarters — Last year's exceptional Q1 growth (86% in individual rated) creates a high base; sustaining 20%+ growth for the full year requires strong performance in subsequent quarters..

Promise ledger

Scorecard data is being built as historical quarters are processed.